Valuation: Takeda Pharmaceutical Company Limited

Market Cap 9,529B 60.55B 52.91B 49.73B 45.38B 85.18B 5,788B 85.19B 597B 230B 2,956B 227B 222B P/E 2027 *
47.3x
P/E 2028 * 30x
Enterprise Value 13,436B 85.37B 74.61B 70.12B 63.99B 120B 8,161B 120B 842B 325B 4,168B 321B 314B EV / Sales 2027 *
2.86x
EV / Sales 2028 * 2.76x
Free-Float
99.26%
Yield 2027 *
3.42%
Yield 2028 * 3.49%
1 week+2.31%
Current month+7.61%
1 month+7.61%
3 months+23.47%
6 months+8.20%
Current year+26.33%
1 week 32.5
Extreme 32.5
33.45
1 month 30.9
Extreme 30.9
33.45
3 years 22.95
Extreme 22.95
33.45
5 years 22.95
Extreme 22.95
33.45
10 years 22.95
Extreme 22.95
49.6
Manager TitleAgeSince
Chief Executive Officer 56 01/01/2025
Director of Finance/CFO 48 01/04/2024
Chief Tech/Sci/R&D Officer 47 01/02/2022
Director TitleAgeSince
Director/Board Member 60 01/06/2015
Director/Board Member 73 01/01/2019
Director/Board Member 48 01/06/2024
Change 5-day change 1-year change 3-year change Capi.($)
0.00%+2.88%+30.39%+11.32% 60.55B
+0.45%+3.00%+55.00%+112.54% 1,043B
-0.10%+0.74%+54.52%+67.72% 649B
+0.28%+0.82%+19.15%+73.63% 469B
-0.19%+0.97%+34.30%+45.99% 355B
+0.28%+2.30%+18.47%+26.67% 270B
+0.89%+4.59%+10.19%+14.72% 262B
+4.34%+9.21%+43.44%+53.25% 222B
+1.40%+4.35%+35.72%+103.53% 189B
-0.46%-6.20%-32.46%-59.65% 175B
Average +0.73%+2.20%+26.87%+44.97% 403.67B
Weighted average by Cap. +0.49%+2.19%+36.30%+66.28%

Financials

2027 *2028 *
Net sales 4,704B 29.89B 26.12B 24.55B 22.4B 42.04B 2,857B 42.05B 295B 114B 1,459B 112B 110B 4,794B 30.46B 26.62B 25.02B 22.83B 42.85B 2,912B 42.86B 300B 116B 1,487B 114B 112B
Net income 196B 1.25B 1.09B 1.03B 936M 1.76B 119B 1.76B 12.31B 4.75B 60.95B 4.69B 4.59B 323B 2.05B 1.79B 1.68B 1.54B 2.88B 196B 2.89B 20.21B 7.8B 100B 7.7B 7.53B
Net Debt 3,907B 24.82B 21.69B 20.39B 18.6B 34.92B 2,373B 34.92B 245B 94.42B 1,212B 93.21B 91.17B 3,702B 23.52B 20.56B 19.32B 17.63B 33.09B 2,249B 33.1B 232B 89.48B 1,148B 88.34B 86.4B
Logo Takeda Pharmaceutical Company Limited
Takeda Pharmaceutical Co Ltd is a Japan-based company mainly engaged in the research, development, manufacturing and global sales of a wide range of pharmaceuticals. Its main business areas are divided into six, including gastroenterology, rare diseases, plasma-derived therapies, oncology (cancer), vaccines, and neuroscience (neuropsychiatric disorders). In research and development, the Company focuses on three priority disease areas, including gastroenterology and inflammatory diseases, neuroscience, and oncology, and also focuses on plasma-derived therapies.
Employees
-
Date Price Change
23/09/26 33.25 0.00%
22/09/26 €33.25 0.00%
21/09/26 €33.25 0.00%
18/09/26 €33.25 0.00%
17/09/26 €33.25 +1.06%
Trader
Investor
Global
Quality
ESG MSCI
AA
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
16
Last Close Price
5,968.00JPY
Average target price
6,622.06JPY
Spread / Average Target
+10.96%

Quarterly revenue - Rate of surprise

-40%: Exceptional extension
d
:
:
SEIZE THE OFFER!